With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn

Bristol-Myers and AstraZeneca’s acquisition of Amylin as part of a 50-50 collaboration brings a big new player into the fast-growing GLP-1 class, which is emerging as a key component of treatment in the large, but highly competitive Type 2 diabetes market.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet